CAR T cell therapy for solid tumours is the cancer new product development equivalent of the quest for the “Holy Grail.” It remains one of the cell therapy challenges of the coming decade.
Light inspires and illuminates
In this post we shine the light on one of the world’s leading cell therapy experts who is taking on that challenge.
Most of our posts are what is known in the business as “long-form” and this one is no exception; it’s over 7,000 words long and offers a veritable smorgasbord of insights into new cell therapies for blood cancers and solid tumours, novel targets, as well as future directions, including a company in stealth mode…
Curious to learn more about this important topic on cracking the code and the quest to find solutions?
Then consider supporting independent science journalism by joining an exclusive group of readers around the world in academic medicine and industry who read BSB premium content.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, plus an expert interview from a cellular therapy specialist in stealth mode, subscribers can log-in or you can click to gain access to BSB Premium Content.
In our latest expert interview, we depart from the usual focus on one of two particular or narrow topics and indulge in a more wide ranging discussion to explore a variety of issues facing the IO field and look at them from the perspective of a researcher who is experienced in working with antibodies in various forms.
We cover a lot of ground from CAR-T cells to bispecifics to NK cells – while many people in industry may see these approaches as separate modalities in different niches, in the future we may well see a greater convergent and opportunities for regimens and combinations rather than a more nihilistic either/or approach.
I have long been fascinated with design of molecules and how different tweaks or enhancements can change the way something works – for better or worse. Just as we have learned much from immune agonists and their biphasic curves that result from constant stimulation (and ways to fix that too), so too will we see CARs, T cell engagers, and NK cell therapies adapt and improve in terms of how they are constructed.
Who better to talk about these changes and the learnings to be had lately than someone who has built and tested many antibodies for a living and is now running his own company?
To learn get a heads up on insights from an expert interview in the CAR T cell space plus our latest company analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
ASH19 in Orlando, FL
Orlando: In the second of our ASH19 reports, we offer a comprehensive and in-depth look at important data presented over the weekend where we breakdown some of the key findings or trial readouts, which are likely of interest to many readers given the heightened attention on novel therapeutic approaches.
Whether the hematologic malignancy is myeloma, leukemia, or lymphoma, we have been rather spoiled for choice in selections for hot topics to discuss this year, so the series will likely run all week!
Here’s the second of our detailed ASH notes…
To learn more from our latest oncology conference insights and get a heads up on our latest ASH Coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
Several groups have banded together to produce the first CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (Twitter #cicon15) which focuses on the science underlying the immune system as it relates to cancer. You can view the program agenda here.
These groups include the American Association for Cancer Research (AACR), Cancer Research Institute (CRI), Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI).
We’ll hopefully be covering key abstracts at this event over the next few days and reporting on not only what the data is, but also the broader significance of the findings.
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.